AAAAAA

   
Results: 1-25 | 26-44
Results: 1-25/44
COMMUNITY ADVISORY BOARDS - THEIR ROLE IN AIDS CLINICAL-TRIALS
Authors: COX LE ROUFF JR SVENDSEN KH MARKOWITZ M ABRAMS DI
Citation: Le. Cox et al., COMMUNITY ADVISORY BOARDS - THEIR ROLE IN AIDS CLINICAL-TRIALS, Health & social work, 23(4), 1998, pp. 290-297
RESISTANCE TO HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 PROTEASE INHIBITORS
Authors: BODEN D MARKOWITZ M
Citation: D. Boden et M. Markowitz, RESISTANCE TO HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 PROTEASE INHIBITORS, Antimicrobial agents and chemotherapy, 42(11), 1998, pp. 2775-2783
GENOTYPIC AND PHENOTYPIC CHARACTERIZATION OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 VARIANTS ISOLATE FROM PATIENTS TREATED WITH THE PROTEASE INHIBITOR NELFINAVIR
Authors: PATICK AK DURAN M CAO Y SHUGARTS D KELLER MR MAZABEL E KNOWLES M CHAPMAN S KURITZKES DR MARKOWITZ M
Citation: Ak. Patick et al., GENOTYPIC AND PHENOTYPIC CHARACTERIZATION OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 VARIANTS ISOLATE FROM PATIENTS TREATED WITH THE PROTEASE INHIBITOR NELFINAVIR, Antimicrobial agents and chemotherapy, 42(10), 1998, pp. 2637-2644
QUANTITATION OF HIV-1-SPECIFIC CYTOTOXIC T-LYMPHOCYTES AND PLASMA LOAD OF VIRAL-RNA
Authors: OGG GS JIN X BONHOEFFER S DUNBAR PR NOWAK MA MONARD S SEGAL JP CAO YZ ROWLANDJONES SL CERUNDOLO V HURLEY A MARKOWITZ M HO DD NIXON DF MCMICHAEL AJ
Citation: Gs. Ogg et al., QUANTITATION OF HIV-1-SPECIFIC CYTOTOXIC T-LYMPHOCYTES AND PLASMA LOAD OF VIRAL-RNA, Science, 279(5359), 1998, pp. 2103-2106
RHEUMATIC-FEVER - A HALF-CENTURY PERSPECTIVE
Authors: MARKOWITZ M
Citation: M. Markowitz, RHEUMATIC-FEVER - A HALF-CENTURY PERSPECTIVE, Pediatrics (Evanston), 102(1), 1998, pp. 272-274
GENOTYPIC CHANGES IN HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 ASSOCIATED WITH LOSS OF SUPPRESSION OF PLASMA VIRAL-RNA LEVELS IN SUBJECTS TREATEDWITH RITONAVIR (NORVIR) MONOTHERAPY
Authors: EASTMAN PS MITTLER J KELSO R GEE C BOYER E KOLBERG J URDEA M LEONARD JM NORBECK DW MO HM MARKOWITZ M
Citation: Ps. Eastman et al., GENOTYPIC CHANGES IN HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 ASSOCIATED WITH LOSS OF SUPPRESSION OF PLASMA VIRAL-RNA LEVELS IN SUBJECTS TREATEDWITH RITONAVIR (NORVIR) MONOTHERAPY, Journal of virology, 72(6), 1998, pp. 5154-5164
RAPID, TRANSIENT CHANGES AT THE ENV LOCUS OF PLASMA HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 POPULATIONS DURING THE EMERGENCE OF PROTEASE INHIBITOR RESISTANCE
Authors: DELWART EL PAN H NEUMANN A MARKOWITZ M
Citation: El. Delwart et al., RAPID, TRANSIENT CHANGES AT THE ENV LOCUS OF PLASMA HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 POPULATIONS DURING THE EMERGENCE OF PROTEASE INHIBITOR RESISTANCE, Journal of virology, 72(3), 1998, pp. 2416-2421
A PRELIMINARY EVALUATION OF NELFINAVIR MESYLATE, AN INHIBITOR OF HUMAN-IMMUNODEFICIENCY-VIRUS (HIV)-1 PROTEASE, TO TREAT HIV-INFECTION
Authors: MARKOWITZ M CONANT M HURLEY A SCHLUGER R DURAN M PETERKIN J CHAPMAN S PATICK A HENDRICKS A YUEN GJ HOSKINS W CLENDENINN N HO DD
Citation: M. Markowitz et al., A PRELIMINARY EVALUATION OF NELFINAVIR MESYLATE, AN INHIBITOR OF HUMAN-IMMUNODEFICIENCY-VIRUS (HIV)-1 PROTEASE, TO TREAT HIV-INFECTION, The Journal of infectious diseases, 177(6), 1998, pp. 1533-1540
HIV-1 ANTIGEN-SPECIFIC AND ANTIGEN-NONSPECIFIC B-CELL RESPONSES ARE SENSITIVE TO COMBINATION ANTIRETROVIRAL THERAPY
Authors: MORRIS L BINLEY JM CLAS BA BONHOEFFER S ASTILL TP KOST R HURLEY A CAO YZ MARKOWITZ M HO DD MOORE JP
Citation: L. Morris et al., HIV-1 ANTIGEN-SPECIFIC AND ANTIGEN-NONSPECIFIC B-CELL RESPONSES ARE SENSITIVE TO COMBINATION ANTIRETROVIRAL THERAPY, The Journal of experimental medicine, 188(2), 1998, pp. 233-245
THE CASE FOR DIVERSITY AND POLITICAL CORRECTNESS
Authors: MARKOWITZ M
Citation: M. Markowitz, THE CASE FOR DIVERSITY AND POLITICAL CORRECTNESS, EDN, 43(24), 1998, pp. 33-33
WELCOME TO THE RE-ENGINEERED EDN
Authors: MARKOWITZ M
Citation: M. Markowitz, WELCOME TO THE RE-ENGINEERED EDN, EDN, 43(23), 1998, pp. 37-37
ANTIVIRAL ACTIVITY OF THE DIHYDROPYRONE PNU-140690, A NEW NONPEPTIDICHUMAN-IMMUNODEFICIENCY-VIRUS PROTEASE INHIBITOR
Authors: POPPE SM SLADE DE CHONG KT HINSHAW RR PAGANO PJ MARKOWITZ M HO DD MO H GORMAN RR DUEWEKE TJ THAISRIVONGS S TARPLEY WG
Citation: Sm. Poppe et al., ANTIVIRAL ACTIVITY OF THE DIHYDROPYRONE PNU-140690, A NEW NONPEPTIDICHUMAN-IMMUNODEFICIENCY-VIRUS PROTEASE INHIBITOR, Antimicrobial agents and chemotherapy, 41(5), 1997, pp. 1058-1063
HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 MESSENGER-RNA SPLICING PATTERN ININFECTED PERSONS IS DETERMINED BY THE PROPORTION OF NEWLY INFECTED-CELLS
Authors: VESANEN M MARKOWITZ M CAO YZ HO DD SAKSELA K
Citation: M. Vesanen et al., HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 MESSENGER-RNA SPLICING PATTERN ININFECTED PERSONS IS DETERMINED BY THE PROPORTION OF NEWLY INFECTED-CELLS, Virology, 236(1), 1997, pp. 104-109
IDENTIFICATION OF A RESERVOIR FOR HIV-1 IN PATIENTS ON HIGHLY-ACTIVE ANTIRETROVIRAL THERAPY
Authors: FINZI D HERMANKOVA M PIERSON T CARRUTH LM BUCK C CHAISSON RE QUINN TC CHADWICK K MARGOLICK J BROOKMEYER R GALLANT J MARKOWITZ M HO DD RICHMAN DD SILICIANO RF
Citation: D. Finzi et al., IDENTIFICATION OF A RESERVOIR FOR HIV-1 IN PATIENTS ON HIGHLY-ACTIVE ANTIRETROVIRAL THERAPY, Science, 278(5341), 1997, pp. 1295-1300
DECAY CHARACTERISTICS OF HIV-1-INFECTED COMPARTMENTS DURING COMBINATION THERAPY
Authors: PERELSON AS ESSUNGER P CAO YZ VESANEN M HURLEY A SAKSELA K MARKOWITZ M HO DD
Citation: As. Perelson et al., DECAY CHARACTERISTICS OF HIV-1-INFECTED COMPARTMENTS DURING COMBINATION THERAPY, Nature, 387(6629), 1997, pp. 188-191
DIFFERENTIAL REGULATION OF THE ANTIBODY-RESPONSES TO GAG AND ENV PROTEINS OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1
Authors: BINLEY JM KLASSE PJ CAO YZ JONES I MARKOWITZ M HO DD MOORE JP
Citation: Jm. Binley et al., DIFFERENTIAL REGULATION OF THE ANTIBODY-RESPONSES TO GAG AND ENV PROTEINS OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1, Journal of virology, 71(4), 1997, pp. 2799-2809
DESIGN-CONTEST VICTOR WINS BMW Z3 ROADSTER
Authors: MARKOWITZ M
Citation: M. Markowitz, DESIGN-CONTEST VICTOR WINS BMW Z3 ROADSTER, EDN, 42(26), 1997, pp. 16-16
EDN, MU-C VENDORS JOIN FORCES TO DEVELOP BENCHMARKS
Authors: MARKOWITZ M
Citation: M. Markowitz, EDN, MU-C VENDORS JOIN FORCES TO DEVELOP BENCHMARKS, EDN, 42(16), 1997, pp. 11-11
ORDERED ACCUMULATION OF MUTATIONS IN HIV PROTEASE CONFERS RESISTANCE TO RITONAVIR
Authors: MOLLA A KORNEYEVA M GAO Q VASAVANONDA S SCHIPPER PJ MO HM MARKOWITZ M CHERNYAVSKIY T NIU P LYONS N HSU A GRANNEMAN GR HO DD BOUCHER CAB LEONARD JM NORBECK DW KEMPF DJ
Citation: A. Molla et al., ORDERED ACCUMULATION OF MUTATIONS IN HIV PROTEASE CONFERS RESISTANCE TO RITONAVIR, Nature medicine, 2(7), 1996, pp. 760-766
DESIGN, SYNTHESIS, AND RESISTANCE PATTERNS OF MP-134 AND MP-167, 2 NOVEL INHIBITORS OF HIV TYPE-1 PROTEASE
Authors: MO HM MARKOWITZ M MAJER P BURT SK GULNIK SV SUVOROV LI ERICKSON JW HO DD
Citation: Hm. Mo et al., DESIGN, SYNTHESIS, AND RESISTANCE PATTERNS OF MP-134 AND MP-167, 2 NOVEL INHIBITORS OF HIV TYPE-1 PROTEASE, AIDS research and human retroviruses, 12(1), 1996, pp. 55-61
HIV-1 VARIANTS ISOLATED FROM PATIENTS TREATED WITH THE PROTEASE INHIBITOR, NELFINAVIR ARE NOT CROSS-RESISTANT TO OTHER PROTEASE INHIBITORS
Authors: PATICK AK DURAN M CAO Y HO T ZHOU P KELLER MR PETERKIN J CHAPMAN S ANDERSON R HO D MARKOWITZ M
Citation: Ak. Patick et al., HIV-1 VARIANTS ISOLATED FROM PATIENTS TREATED WITH THE PROTEASE INHIBITOR, NELFINAVIR ARE NOT CROSS-RESISTANT TO OTHER PROTEASE INHIBITORS, AIDS, 10, 1996, pp. 92-92
ANTIVIRAL AND RESISTANCE STUDIES OF AG1343, AN ORALLY BIOAVAILABLE INHIBITOR OF HUMAN-IMMUNODEFICIENCY-VIRUS PROTEASE (VOL 40, PG 294, 1996)
Authors: PATICK AK MO H MARKOWITZ M APPELT K WU B MUSICK L KALISH V KALDOR S REICH S HO D WEBBER S
Citation: Ak. Patick et al., ANTIVIRAL AND RESISTANCE STUDIES OF AG1343, AN ORALLY BIOAVAILABLE INHIBITOR OF HUMAN-IMMUNODEFICIENCY-VIRUS PROTEASE (VOL 40, PG 294, 1996), Antimicrobial agents and chemotherapy, 40(6), 1996, pp. 1575-1575
ANTIVIRAL AND RESISTANCE STUDIES OF AG1343, AN ORALLY BIOAVAILABLE INHIBITOR OF HUMAN-IMMUNODEFICIENCY-VIRUS PROTEASE
Authors: PATICK AK MARKOWITZ M APPELT K WU B MUSICK L KALISH V KALDOR S REICH S HO D WEBBER S
Citation: Ak. Patick et al., ANTIVIRAL AND RESISTANCE STUDIES OF AG1343, AN ORALLY BIOAVAILABLE INHIBITOR OF HUMAN-IMMUNODEFICIENCY-VIRUS PROTEASE, Antimicrobial agents and chemotherapy, 40(2), 1996, pp. 292-297
HIV-1 DYNAMICS IN-VIVO - VIRION CLEARANCE RATE, INFECTED CELL LIFE-SPAN, AND VIRAL GENERATION TIME
Authors: PERELSON AS NEUMANN AU MARKOWITZ M LEONARD JM HO DD
Citation: As. Perelson et al., HIV-1 DYNAMICS IN-VIVO - VIRION CLEARANCE RATE, INFECTED CELL LIFE-SPAN, AND VIRAL GENERATION TIME, Science, 271(5255), 1996, pp. 1582-1586
COST-EFFECTIVENESS MODEL FOR ESTIMATING THE VALUE OF LAMOTRIGINE (LAMICTAL) - A NEW DRUG FOR EPILEPSY TREATMENT
Authors: MAUSKOPF J MARKOWITZ M HALPERN MT MURRAY M
Citation: J. Mauskopf et al., COST-EFFECTIVENESS MODEL FOR ESTIMATING THE VALUE OF LAMOTRIGINE (LAMICTAL) - A NEW DRUG FOR EPILEPSY TREATMENT, Neurology, 46(2), 1996, pp. 4132-4132
Risultati: 1-25 | 26-44